MIT uses AI to design thermostable mRNA vaccines that need no cold chain
rohanpaul_ai · x · 2026-10-01
MIT engineers used AI to find a new mRNA vaccine formulation that stabilizes the lipid nanoparticles, letting vaccines sit at room temperature for a full year and survive 100°F heat for two months.
- Removes the cold-chain barrier for distributing vaccines to poor countries
- Could enable easy skin-patch delivery instead of shots
- AI replaced exhaustive trial-and-error, reaching a thermostable formulation in weeks instead of months
The work applies to RNA vaccines being developed for cancer and other diseases as well.
Related event: MIT Uses AI to Make mRNA Vaccines Stable at Room Temperature for a Year(2 posts)→
More from Research
- In business, Type 2 errors often cost more than Type 1 errors — mdancho84 · 2026-11-16
- In risk management, missing a real risk can sink the business — mdancho84 · 2026-11-16
- Cost of Type 2 error: a missed pregnancy delays prenatal care — mdancho84 · 2026-11-16
- Cost of Type 1 error: a false alarm is usually temporary and clarifiable — mdancho84 · 2026-11-16
- Thread defines Type 2 error: false negative means missing a real effect — mdancho84 · 2026-11-16
- Thread defines Type 1 error via pregnancy test: false positive explained — mdancho84 · 2026-11-16